GoodRx Holdings (GDRX) Stock Overview
Offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
GDRX Community Fair Values
Create NarrativeSee what 26 others think this stock is worth. Follow their fair value or set your own to get alerts.
GoodRx Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.05 |
| 52 Week High | US$5.81 |
| 52 Week Low | US$1.77 |
| Beta | 1.47 |
| 1 Month Change | -10.09% |
| 3 Month Change | -28.07% |
| 1 Year Change | -49.88% |
| 3 Year Change | -64.72% |
| 5 Year Change | -94.74% |
| Change since IPO | -95.94% |
Recent News & Updates
Recent updates
GoodRx: Losing Relevance With Consumers (Downgrade)
Mar 09Investors Don't See Light At End Of GoodRx Holdings, Inc.'s (NASDAQ:GDRX) Tunnel And Push Stock Down 33%
Nov 01
Should You Think About Buying GoodRx Holdings, Inc. (NASDAQ:GDRX) Now?
Oct 02GoodRx Holdings' (NASDAQ:GDRX) Performance Is Even Better Than Its Earnings Suggest
Aug 15Little Excitement Around GoodRx Holdings, Inc.'s (NASDAQ:GDRX) Revenues As Shares Take 28% Pounding
Aug 08GoodRx Holdings, Inc. (NASDAQ:GDRX) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected
Jun 24GoodRx Holdings (NASDAQ:GDRX) May Have Issues Allocating Its Capital
May 23
Pharma Manufacturer Solutions Expansion Will Improve Prescription Access
GoodRx aims to boost revenue by expanding Pharma Manufacturer Solutions and enhancing the prescription marketplace, aligning with partners' economic needs.GoodRx: Great Value For Patient Investors (Upgrade)
Mar 24GoodRx: A Business In Transition, But It Has Likely Reached Its Low (Rating Upgrade)
Jan 08Capital Allocation Trends At GoodRx Holdings (NASDAQ:GDRX) Aren't Ideal
Dec 21GoodRx Holdings, Inc.'s (NASDAQ:GDRX) Shares May Have Run Too Fast Too Soon
Oct 29GoodRx: The Tide Is Turning The Wrong Way (Rating Downgrade)
Oct 26GoodRx Holdings: Failing To Gain Much Traction
Oct 08GoodRx Holdings' (NASDAQ:GDRX) Returns On Capital Not Reflecting Well On The Business
Sep 22GoodRx Q2 Earnings Preview
Jul 31GoodRx Holdings (NASDAQ:GDRX) Could Easily Take On More Debt
Jul 12GoodRx Holdings, Inc.'s (NASDAQ:GDRX) 30% Price Boost Is Out Of Tune With Revenues
Jun 09Returns On Capital At GoodRx Holdings (NASDAQ:GDRX) Paint A Concerning Picture
Jun 06Shareholder Returns
| GDRX | US Healthcare Services | US Market | |
|---|---|---|---|
| 7D | 4.6% | -1.5% | 1.2% |
| 1Y | -49.9% | -29.4% | 32.8% |
Return vs Industry: GDRX underperformed the US Healthcare Services industry which returned -29.9% over the past year.
Return vs Market: GDRX underperformed the US Market which returned 31.9% over the past year.
Price Volatility
| GDRX volatility | |
|---|---|
| GDRX Average Weekly Movement | 10.8% |
| Healthcare Services Industry Average Movement | 10.2% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: GDRX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: GDRX's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 697 | Wendy Barnes | www.goodrx.com |
GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscription programs and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform.
GoodRx Holdings, Inc. Fundamentals Summary
| GDRX fundamental statistics | |
|---|---|
| Market cap | US$709.13m |
| Earnings (TTM) | US$30.44m |
| Revenue (TTM) | US$796.85m |
Is GDRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GDRX income statement (TTM) | |
|---|---|
| Revenue | US$796.85m |
| Cost of Revenue | US$57.60m |
| Gross Profit | US$739.26m |
| Other Expenses | US$708.82m |
| Earnings | US$30.44m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.089 |
| Gross Margin | 92.77% |
| Net Profit Margin | 3.82% |
| Debt/Equity Ratio | 79.2% |
How did GDRX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/07 03:48 |
| End of Day Share Price | 2026/04/07 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
GoodRx Holdings, Inc. is covered by 25 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Glen Santangelo | Barclays |
| Allen Lutz | BofA Global Research |
| Daniel Grosslight | Citigroup Inc |